Frazier Life Sciences Management, L.P. Design Therapeutics, Inc. Call Options Transaction History
Frazier Life Sciences Management, L.P.
- $1.86 Billion
- Q3 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding DSGN
# of Institutions
102Shares Held
30.3MCall Options Held
2.3KPut Options Held
16.5K-
Sr One Capital Management, LP6.53MShares$39.3 Million11.88% of portfolio
-
Logos Global Management LP San Francisco, CA4.22MShares$25.4 Million3.0% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$13.9 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY1.74MShares$10.5 Million0.1% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.6MShares$9.64 Million0.02% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $336M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...